PPIs and Dementia: Association or Cause

Does taking a PPI cause dementia?

No study has proven that proton pump inhibitors cause dementia. What exists is an association found in some large observational datasets — people who took PPIs for years showed a modestly higher rate of dementia diagnoses than people who didn't — but association studies like these cannot rule out that something else entirely explains the pattern.

Many people are started on a PPI after a short empiric trial for classic heartburn and regurgitation, and once symptoms settle, the prescription often just continues without a scheduled point to reassess it 1Ref 1Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ (2022).ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.Explains the empiric PPI-trial pathway that puts many patients on a PPI long enough for a long-term-safety question like dementia to arise.. That's part of why so many people have been on one long enough for a question like this to even come up. This is fundamentally a PPI association vs causation problem, and it's worth understanding that distinction before deciding what a finding like this actually means for a prescription taken for years rather than weeks.

A proven causal effect and a statistical association are different claims requiring different kinds of evidence. Causation generally needs a randomized trial, where a coin flip decides who takes the drug and who doesn't, removing the possibility that healthier or sicker people simply sorted themselves into each group. Nobody has run that trial for PPIs and dementia, and given how long dementia takes to develop, one may never be practical to run.

What an expert review of long-term PPI safety concluded

The American Gastroenterological Association published a formal review of long-term PPI risks and benefits, weighing the dementia claim alongside other purported harms, including ppis and kidney disease, fracture risk, and nutrient deficiency 2Ref 2Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.Supports the AGA's long-term PPI risk/benefit conclusion: benefits generally outweigh purported risks including dementia when appropriately indicated, at the lowest effective dose, given insufficient evidence for routine mitigation strategies.. Its conclusion was not reassurance without limits — it was narrower and more useful than that: for patients who have a clear reason to be on a PPI, the benefits generally outweigh these purported risks, and there isn't enough evidence to support routine strategies aimed at preventing them 2Ref 2Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.Supports the AGA's long-term PPI risk/benefit conclusion: benefits generally outweigh purported risks including dementia when appropriately indicated, at the lowest effective dose, given insufficient evidence for routine mitigation strategies..

The review found no evidence strong enough to justify stopping a needed PPI over the dementia question alone. Its practical takeaway is closer to using the lowest effective dose and periodically revisiting whether it's still needed than to a blanket reassurance or a blanket alarm 2Ref 2Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.Supports the AGA's long-term PPI risk/benefit conclusion: benefits generally outweigh purported risks including dementia when appropriately indicated, at the lowest effective dose, given insufficient evidence for routine mitigation strategies.. That distinction is different from stopping abruptly or avoiding a medication that may be treating real, sometimes serious, disease.

When continuing a PPI is the clearer call

Some conditions are a clear reason to keep taking a PPI regardless of the dementia question. Erosive esophagitis, Barrett's esophagus — a change in the tissue lining the lower esophagus caused by chronic acid exposure — and a documented history of bleeding ulcers all call for continued acid suppression, because the risk of stopping treatment for those conditions is concrete and immediate, while the dementia association remains unproven 3Ref 3Targownik LE, Fisher DA, Saini SD (2022).AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.Supports which patients should continue a PPI (erosive esophagitis, Barrett's, bleeding-risk indications) versus attempt to step down or stop..

Barrett's esophagus is itself a known complication of chronic reflux, and it's one of the specific situations in which continuing PPI therapy is recommended rather than trialed off 4Ref 4Shaheen NJ, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG, Wani S (2022).Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline.Supports that Barrett's esophagus is a chronic-GERD complication in which continuing PPI therapy is specifically recommended.. For someone in one of these categories, the more useful question isn't whether to stop, but whether the dose and monitoring plan still make sense — a conversation for a scheduled follow-up, not a reason to skip doses or ration medication out of worry over a headline.

Who might not need to stay on one

A large share of long-term PPI use has no clear ongoing indication — the prescription outlived the reason it started, or symptoms improved and nobody revisited whether the medication was still necessary. For that group, the same expert guidance recommends attempting to step down or stop under a clinician's guidance, rather than continuing indefinitely by default 3Ref 3Targownik LE, Fisher DA, Saini SD (2022).AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.Supports which patients should continue a PPI (erosive esophagitis, Barrett's, bleeding-risk indications) versus attempt to step down or stop..

Coming off a PPI is its own process, with its own rebound-acid considerations if it's stopped too abruptly. Tapering off a ppi is covered in more depth elsewhere, and it's worth reading before making any change to a long-running prescription. The dementia question can be a reasonable prompt to raise that conversation; on its own, it isn't a reason to change anything without a clinician involved in the plan.

How proton pump inhibitors actually work, and why the safety questions cluster here

Proton pump inhibitors block acid-producing cells in the stomach lining more completely, and for longer, than older drugs like antacids or H2 blockers, which is part of why they draw more long-term safety questions than those alternatives do. Understanding how proton pump inhibitors actually work explains the shape of the whole conversation: less stomach acid changes digestion and absorption in ways that ripple outward, and each of those ripples has become its own research question rather than one shared verdict.

Suppressing acid for years can change how the body absorbs certain nutrients, which is the basis of a separate ppis and nutrient levels conversation, distinct from anything about the brain. The same 2017 review that examined the dementia claim also looked at ppis and infection risk as a separate purported harm, and reached a similarly cautious, evidence-first conclusion rather than either dismissing or confirming it outright 2Ref 2Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.Supports the AGA's long-term PPI risk/benefit conclusion: benefits generally outweigh purported risks including dementia when appropriately indicated, at the lowest effective dose, given insufficient evidence for routine mitigation strategies..

Why this is a conversation, not a decision to make alone

The dementia question is a legitimate reason to ask why a PPI prescription still makes sense — it isn't, on its own, a reason to stop one unilaterally. A clinician can weigh the original indication, how long the medication has been running, and whether stepping down or switching to an as-needed approach fits the specific situation, which works far better than reacting to a single alarming headline or stopping cold.

Bringing a written list of current medications, including anything over-the-counter, to the next appointment makes that conversation more productive than trying to reconstruct history from memory. An association is not a diagnosis, and this one hasn't been shown to be causal. The honest state of the evidence — reviewed carefully and found insufficient to drive blanket changes — is itself useful information, even without a tidy verdict at the end of it.